Abstract
Total therapy 3 is an intensified protocol for multiple myeloma (MM). The "real life" outcomes of this protocol were seldom reported. Data was obtained for 81 patients (newly diagnosed, n=49; progressive MM, n=32), most of which had high-risk parameters. Overall response rate following (V)DT-PACE was 96% and 75% for the newly diagnosed and progressive groups, respectively. Median progression-free survival was 42.5 and 9 months, respectively. The 2-year overall survival was 88% and 40%, respectively. Treatment with (V)DT-PACE achieves high response rate among patients with high-risk disease, which can be translated into long-term remission only for newly diagnosed patients.
Keywords:
(V)DT-PACE; Bone disease; High dose therapy; High risk; Multiple myeloma; Total therapy.
Copyright © 2014 Elsevier Ltd. All rights reserved.
MeSH terms
-
Adult
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Cisplatin / administration & dosage
-
Cisplatin / adverse effects
-
Cyclophosphamide / administration & dosage
-
Cyclophosphamide / adverse effects
-
Dexamethasone / administration & dosage
-
Dexamethasone / adverse effects
-
Disease-Free Survival
-
Doxorubicin / administration & dosage
-
Doxorubicin / adverse effects
-
Etoposide / administration & dosage
-
Etoposide / adverse effects
-
Female
-
Follow-Up Studies
-
Humans
-
Male
-
Middle Aged
-
Multiple Myeloma / drug therapy*
-
Multiple Myeloma / mortality*
-
Retrospective Studies
-
Salvage Therapy / methods*
-
Survival Rate
-
Thalidomide / administration & dosage
-
Thalidomide / adverse effects
Substances
-
Thalidomide
-
Etoposide
-
Dexamethasone
-
Doxorubicin
-
Cyclophosphamide
-
Cisplatin